Vivex Biologics Says VIA Disc NP Met Primary Endpoint in ASCEND Trial
Vivex Biologics said VIA Disc NP met the primary endpoint in the pivotal, sham-controlled ASCEND trial, published in the Journal of Clinical Medicine.
Related stories
INVL Technology to Acquire Its Own Shares
INVL Technology will acquire its own shares after its share buyback ends.
M impact | EQUITY | Oct 29, 2026, 02:02 PM UTC
Medical Properties Reports Third-Quarter 2026 Results
Medical Properties Trust reported third-quarter 2026 net income of $0.34 and normalized funds from operations of $0.11.
M impact | EQUITY | Oct 29, 2026, 02:01 PM UTC
Verizon Reports Third-Quarter Revenue of $34.31B, EPS of $1.25
Verizon reported third-quarter 2026 net income of $5.2 billion. Revenue rose 1.5% year over year, net income increased 5%, and diluted EPS advanced 6.8%.
M impact | EQUITY | Oct 29, 2026, 02:01 PM UTC
Relation Insurance Acquires Wright Insurance Planning
Relation Insurance Services announced the acquisition of Wright Insurance Planning.
M impact | EQUITY | Oct 29, 2026, 02:01 PM UTC
US session market picture: S&P 500 -0.59%, Nasdaq 100 -1.62%; EUR/USD -0.18%, WTI -2.21%, WBD leads volume
US session market picture. US index futures: S and P futures is down 0.59 percent, Nasdaq futures is down 1.62 percent, Dow futures is down 0.48 percent and Russell futures is up 0
M impact | EQUITY | Oct 29, 2026, 02:00 PM UTC
Fino Payments Bank Reports Q2 Net Loss of 209 Million Rupees
M impact | EQUITY | Oct 29, 2026, 01:59 PM UTC